Compare BLFS & AVLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLFS | AVLN |
|---|---|---|
| Founded | 1987 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 2013 | 2026 |
| Metric | BLFS | AVLN |
|---|---|---|
| Price | $29.10 | $28.69 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $32.00 | N/A |
| AVG Volume (30 Days) | ★ 1.0M | 462.0K |
| Earning Date | 05-07-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 77.27 | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $96,214,000.00 | N/A |
| Revenue This Year | $19.73 | N/A |
| Revenue Next Year | $17.82 | N/A |
| P/E Ratio | $1,511.25 | ★ N/A |
| Revenue Growth | ★ 16.97 | N/A |
| 52 Week Low | $17.86 | $25.07 |
| 52 Week High | $30.27 | $33.32 |
| Indicator | BLFS | AVLN |
|---|---|---|
| Relative Strength Index (RSI) | 59.71 | 40.12 |
| Support Level | $23.86 | $27.22 |
| Resistance Level | $29.18 | $29.31 |
| Average True Range (ATR) | 1.29 | 2.30 |
| MACD | 0.06 | -0.19 |
| Stochastic Oscillator | 57.08 | 40.62 |
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.